NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

6 Months Ended

Mar. 31, 2021

7. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of March 31,		As of September 30,
	2021		2020
Accrued compensation and benefits	$	153,688	$	88,527
Accrued consulting settlement		250,000		—
Accrued professional fees		167,829		241,755
Accrued research and development		217,701		41,313
Accrued franchise tax		79,088		155,865
Accrued patent expenses		258,331		24,716
Other accrued expenses		3,706		3,707
Total	$	1,130,343	$	555,883